Dyne Therapeutics, Inc. develops treatments for muscle diseases using its FORCE platform, with promising candidates DYNE-101 ...

Furthermore, impressive results in the DMD program, particularly in exon skipping and dystrophin expression, exceeded expectations, positioning Avidity Biosciences favorably for regulatory discussions ...